Loading...
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
Bruton tyrosine kinase (BTK) is a validated target for treatment of B-cell malignancies, and oral inhibitors of BTK have emerged as a standard of care for these diseases. Acalabrutinib is a second generation, highly selective, potent, covalent BTK inhibitor that exhibits minimal off-target activity...
Na minha lista:
| Udgivet i: | Front Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8162209/ https://ncbi.nlm.nih.gov/pubmed/34055635 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.668162 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|